CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a new ultrasonic nebulization technology for targeted delivery of therapeutics to the lungs. By creating precise aerosol droplets, it seeks to improve treatment efficacy for respiratory diseases and enhance gene therapy accessibility.
According to the WHO 235 million people suffer from asthma and 64M people have chronic obstructive pulmonary disease, leading to 3M deaths per year worldwide.
The cost of treating patients with all forms of lung disease is ~ €380B p.a., leading to the loss of >50M DALYS.
Generally, patients with such respiratory diseases are treated by inhalation of medicines within aerosols, where the therapy (including medicine or biologics used in gene therapy) can be targeted directly to the lung.
The accept…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
